Genetics and Neurobiology of Down Syndrome

Overview Bani Ganguly Preface Bani Ganguly 1. History and Overview of Down Syndrome: Then and Now Bani Ganguly and Nitin Kadam 2. Congenital features and health aspects in Down syndrome Bani Ganguly and Nitin Kadam 3. Chromosomal cause of Down syndrome Bani Ganguly 4. Possible Causes of Chromosomal Non-Disjunction Bani Ganguly 5. Prevention: Prenatal Screening, Testing and Genetic Counseling, and Socio-cultural Aspects of Down Syndrome Bani Ganguly 6. Gene-dosage imbalance of trisomic HSA21 and Genotype-phenotype association in Down syndrome Bani Ganguly 7. Development of specific phenotypes and genetic consequences in Down syndrome: malformations in craniofacial and cardiac anatomy, and development of leukemia and cognitive and learning deficits Bani Ganguly 8. Mitochondrial dysfunction in Down syndrome Bani Ganguly 9. Mitochondrial abnormalities on patho-biology in Down syndrome Bani Ganguly 10. Neurogenesis and genetic consequences in Down syndrome Bani Ganguly 11. Glutamatergic and GABAergic mechanisms and therapeutic targets in Down Syndrome Bani Ganguly 12. Alzheimer Disease in Down syndrome (DSAD) Bani Ganguly 13. MicroRNAs and epigenetic signatures in Down syndrome Bani Ganguly 14. In vivo and in vitro models for research on Down syndrome Bani Ganguly

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Neurociências
• Genética (não médica)

Ass Alzheimer disease; and tau proteins; Antenatal complexity; APP; Brain development; Brain plasticity; Cardiac defects; Causes of chromosomal nondisjunction; Cognitive and learning deficits; Congenital heart defect; Cortical circuitry; Craniofacial malformation; Cranio-facial malformations; Deregulated protein; Dosage imbalance; Down syndrome; DS organoids; DS research; DS-derived iPSCs; DS-models; E/I balance; Epigenetic drug targets; Epigenetic modulation in Down syndrome; Ethics of prenatal diagnosis; Exposure to environmental and occupational agents; Fertility in DS; GABA antagonists and allosteric modulators; GABAergic and glutamatergic neurotransmission; GABA-receptors; Genes for phenotypic variability; Genetic counseling; History of Down syndrome; HSA21 dosage imbalance; HSA21 genes; Incidence of down syndrome; Interaction of genes with HSA21Proteomes in Down syndrome; Interaction of HSA21 genes; Leukemia; Maternal age; Meiotic nondisjunction; Meiotic recombination; Microglial dysfunction; microRNAs in Down syndrome; microRNA-targeted drugs; Mitochondrial adaptive response; Mitochondrial diseases of Down syndrome; Mitochondrial dysfunction; Mitochondrial therapeutics; Mitophagy; Mosaic Down syndrome; Neural differentiation; Neurofibrillary tangles; Neuroinflammation; Other HSA21 genes for AD; Oxidative phosphorylation; Oxidative stress; Phenotypes; Preconception and prenatal screening; Racial or ethnic variations; Redox and calcium homeostasis; Risk of recurrence; Robertsonian translocation; SARS-COV-2Socio-cultural aspects of Down syndrome; Support of public health; Transcriptomes of trisomy 21Trisomy 21Trisomic HSA21Trisomic mice; Trisomy 21